WARNINGS The product, although presenting a very poor systemic absorption, must be used with caution in subjects suffering from hypertension, hyperthyroidism, heart disorders, bronchial asthma and hyperglycemia (diabetes). The product should be kept out of the reach of children as accidental ingestion can cause CNS depression (rapid sedation and hypotonia), coma. In these cases, immediate medical assistance is always required. The product is not suitable for the treatment of infections, mechanical (trauma), chemical or heat damage or to eliminate foreign bodies in the eye. These situations require medical attention. The 10 ml bottle contains benzalkonium chloride. May cause eye irritation during treatment, soft contact lenses should not be worn. Since benzalkonium chloride is not present in the single-dose package, this can be used by contact lens wearers, or by those who show hypersensitivity to benzalkonium chloride. PHARMACOTHERAPEUTIC CATEGORY Decongestants and antiallergics. STORAGE Store in the original packaging. CONTRAINDICATIONS / SECONDARY EFFECT Hypersensitivity to the active substance or to any of the listed excipients or to other closely related substances from a chemical point of view; in particular towards xylometazoline, oximetazoline, tetrizoline; narrow-angle glaucoma or other serious eye diseases; children under 12 years of age; simultaneous treatment with monoamine oxidase inhibitors. NAME IMIDAZYL 1 MG / ML EYE DROPS, SOLUTION EXCIPIENTS 10 ml bottle: benzalkonium chloride; sodium chloride; disodium edetate; monobasic sodium phosphate dihydrate; disodium phosphate dihydrate; purified water. Single-dose container: monobasic sodium phosphate; sodium chloride; water for injections. SIDE EFFECTS The use of the product can sometimes cause pupillary dilation, systemic absorption effects (hypertension, cardiac disorders, hyperglycemia), increased intraocular pressure, nausea, headache. Hypersensitivity phenomena may rarely occur. In this case, treatment must be interrupted and appropriate therapy instituted. The reporting of suspected adverse reactions that occur after the authorization of the drug is important, as it allows continuous monitoring of the benefit / risk ratio of the drug. PREGNANCY AND BREASTFEEDING There are no known teratogenic and embryotoxic effects of the specialty component, in topical use. However, in pregnant and lactating women the product should be used only in case of real need. INDICATIONS In allergic and inflammatory states of the conjunctiva characterized by a sense of burning, also from external agents, associated with excessive lacrimation, photophobia, hyperemia. INTERACTIONS The medicine should not be used if you are taking monoamine oxidase inhibitors or if it has been less than two weeks since the last administration of these medicines as serious hypertensive crises may arise. DOSAGE Instill 1-2 drops into the affected eye, 1-2 times a day. Do not exceed the recommended dose. In any case, the product should not be used for more than 4 consecutive days unless otherwise prescribed due to the possibility that unwanted effects may otherwise occur. Strictly adhere to the recommended doses. A higher dosage of the product even if taken topically and for a short period of time can 'give rise to serious systemic effects. ACTIVE PRINCIPLES Nafazoline nitrate.